Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
|Articles|August 11, 2022
Daily OTC Pearl: Mucinex DM
Author(s)Saro Arakelians, PharmD
Mucinex DM is an expectorant and cough suppressant.
Advertisement
OTC/Lifestyle Pearl of the Day: Mucinex DM
Indication: Mucinex DM is an expectorant and cough suppressant.
Insight:
- Helps loosen phlegm and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive. Temporarily relieves cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants; the intensity of coughing; the impulse to cough to help you get to sleep.
- Directions: Do not crush, chew, or break tablet. Take with full glass of water. This product can be administered without regard for timing of meals. Adults and children 12 years and older take 1 tablet every 12 hours but not more than 2 tablets in 24 hours. Children under 12 years of age should not use.
- Active Ingredients: In each extended-release bi-layer tablet: Dextromethorphan HBr (60 mg), guaifenesin (1200 mg). Inactive ingredients: Carbomer homopolymer type B, D&C yellow 10 aluminum lake, hypromellose USP, magnesium stearate NF, microcrystalline cellulose NF, sodium starch glycolate NF.
Source:
Advertisement
Related to this article
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
5